… regulatory processes that led to the approval of gefitinib in July 2015, for the first-line treatment
of patients with metastatic non-small cell lung cancer (NSCLC) that harbors specific types …

… is highly effective for the treatment of advanced non–small-cell lung cancer (NSCLC) with
EGFR … compared with that of standard therapy with EGFR- tyrosine kinase inhibitors alone. …

… gefitinib are approved for first-line treatment of EGFR mutation-positive non-small-cell lung
cancer (… We aimed to compare the efficacy and safety of afatinib and gefitinib in this setting. …

… patients with advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib are the
first-generation EGFR-TKIs for patients … and gefitinib had similar effectiveness but gefitinib had …

… on tumor cells was increased after BRAF inhibitor treatment in … tumor tissues from patients
with non–small-cell lung cancer (… before and after resistance to gefitinib had developed. In …

… , gefitinib adds to the list of recommended first-line treatments for lung cancer harboring EGFR
… , clinical efficacy, and safety of gefitinib in major clinical trials and post-marketing studies. …

… In this study, P+G as first-line therapy significantly prolonged PFS, TtPD, and DoR compared
with gefitinib monotherapy in patients with EGFR mutation–positive NS NSCLC. Although …

… Most patients (afatinib, 72.6%; gefitinib, 76.8%) had at least one subsequent systemic …
cancer treatment following discontinuation of afatinib/gefitinib; 20 (13.7%) and 23 (15.2%) patients …

… safety with that of the reversible EGFR tyrosine kinase inhibitor gefitinib in the first-line
treatment of patients with advanced EGFR-mutation-positive non-small-cell lung cancer (NSCLC). …

9005 Background: Although EGFR-TKI alone has been a standard first-line treatment for pts
with advanced NSCLC with EGFR mutations, our phase II study (NEJ005) showed …